Mabpharm Limited (HK:2181) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Mabpharm Limited has received approval from the Indonesian National Agency of Drug and Food Control for their core product, CMAB008 (infliximab for injection), to treat several conditions including ulcerative colitis and rheumatoid arthritis. This biosimilar medicine, originating from China, offers a more economical option for patients due to its inclusion in China’s basic medical insurance program. Investors may find this approval promising as it expands Mabpharm’s market reach and potential revenue streams.
For further insights into HK:2181 stock, check out TipRanks’ Stock Analysis page.